Cover Story
ClinicalReal-world Evidence
A novel study led by Friends of Cancer Research is providing evidence that tumor response rates can be assessed across real-world data sets, bringing regulators one step closer to potentially building a framework for pre-market evaluation of cancer drugs and post-market tracking of drug performance based on real-world endpoints.
In Brief
Clinical Roundup
Drugs & Targets
NCI Trials
NCI Trials for October 2023
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82
- Trump et al. are wrong: Biden Cancer Initiative is not to be confused with the Beau Biden Cancer Moonshot
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- NCI’s Virtual Clinical Trials Office fills the staffing shortages at cancer centers
- High school science competitions shaped the careers of Regeneron’s co-founders—now, they’re paying it forward
NCI’s Youth Enjoy Science (YES) program also invests in student scientists - How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission